생물제제 안전성 시험 시장 분석 및 예측(-2035년) : 유형, 제품, 기술, 용도, 프로세스, 최종 사용자, 장비, 솔루션, 단계

The global Biologics Safety Testing Market is projected to grow from $4.6 billion in 2025 to $11.9 billion by 2035, at a compound annual growth rate (CAGR) of 9.9%. The biologics safety testing market is driven by the rising production of vaccines, monoclonal antibodies, and advanced biologic therapies, increasing the need for rigorous quality control and contamination testing throughout biologics manufacturing. According to the European Medicines Agency (EMA), more than 100 biosimilar medicines have been authorized in the European Union, each requiring comprehensive analytical comparability and quality assessments to demonstrate comparable quality, safety, and efficacy to the reference biologic. The growing adoption of viral clearance studies, sterility testing, mycoplasma testing, and advanced analytical methods is further driving demand for biologics safety testing solutions.

The Type segment of the Biologics Safety Testing Market includes endotoxin tests, sterility tests, cell line authentication and characterization tests, adventitious agent detection tests, residual host contaminant detection tests, bioburden tests, and others. Among these, endotoxin and sterility testing represent major segments due to their critical role in ensuring the safety, quality, and regulatory compliance of biologics, vaccines, and advanced therapies. Adventitious agent detection is gaining importance with the increasing production of complex biologics and cell-based therapies, as it helps identify potential viral and microbial contaminants. Cell line authentication and characterization tests are also expanding due to the growing adoption of recombinant proteins, monoclonal antibodies, and gene therapies requiring stringent quality control.

The Product segment of the Biologics Safety Testing Market includes instruments, kits & reagents, services, software, and others. Kits & reagents account for a significant market share due to their widespread use in routine safety testing procedures, including microbial detection, endotoxin analysis, and contamination monitoring. Services are witnessing strong growth as pharmaceutical and biotechnology companies increasingly outsource specialized testing activities to contract testing organizations to meet regulatory requirements and improve efficiency. Instruments and software solutions are also gaining traction due to advancements in automation, data management, and high-throughput testing technologies that enhance accuracy and speed in biologics quality assessment.

Geographical Overview

North America held the largest share of the global biologics safety testing market in 2025, driven by its strong biopharmaceutical industry, advanced regulatory framework, and increasing production of biologics, biosimilars, vaccines, and cell and gene therapies. The region is home to leading pharmaceutical companies, contract research organizations (CROs), and contract development and manufacturing organizations (CDMOs) that extensively perform sterility, endotoxin, mycoplasma, adventitious agent, and viral safety testing to ensure product quality and regulatory compliance. Significant investments in biologics research and development, coupled with stringent quality standards enforced by regulatory authorities, have further accelerated demand for comprehensive safety testing services. Additionally, continuous advancements in analytical technologies and increasing outsourcing of quality testing reinforce North America's leadership in the global biologics safety testing market.

Asia Pacific is expected to witness the highest growth in the biologics safety testing market owing to rapid expansion of biopharmaceutical manufacturing, increasing production of biosimilars and vaccines, and growing investments in biotechnology research. Countries such as China, India, South Korea, Japan, and Singapore are strengthening their biologics manufacturing capabilities through government support, expanding GMP-certified facilities, and increasing adoption of international quality standards. Rising demand for contract testing services, growing clinical research activities, and increasing exports of biologic products are further driving market growth. Moreover, the expansion of CROs and CDMOs, along with favorable regulatory reforms and increasing focus on product safety and quality assurance, is expected to position Asia Pacific as the fastest-growing regional market during the forecast period.

Key Trends and Drivers

Increasing Adoption of Advanced Analytical Technologies for Biologics Safety Testing:

The Biologics Safety Testing Market is witnessing a growing trend toward the adoption of advanced analytical technologies, including next-generation sequencing (NGS), polymerase chain reaction (PCR)-based assays, and automated testing platforms. These technologies are improving the speed, sensitivity, and accuracy of detecting contaminants such as viruses, bacteria, mycoplasma, and other impurities in biologic products. Pharmaceutical and biotechnology companies are increasingly integrating advanced testing methods to ensure the safety and quality of complex biologics, including monoclonal antibodies, vaccines, and cell and gene therapies. Additionally, the expansion of personalized medicines and regulatory focus on stringent quality standards are encouraging innovation in biologics safety testing workflows.

Rising Production of Biologics and Stringent Regulatory Safety Requirements:

The increasing production of biologics, biosimilars, vaccines, and advanced therapies is a major driver of the Biologics Safety Testing Market. As biologic products involve complex manufacturing processes using living systems, the need for comprehensive safety testing to detect potential contaminants and ensure product quality has become essential. Regulatory agencies worldwide require extensive characterization and contamination testing before biologics can reach the market, increasing demand for specialized testing services. Furthermore, the growing pipeline of monoclonal antibodies, gene therapies, and cell-based therapies is driving pharmaceutical companies and contract testing organizations to invest in advanced biologics safety testing capabilities.

Research Scope

• Estimates and forecasts the overall market size across type, application, and region.
• Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
• Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
• Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
• Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
• Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
• Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

• 1.1 Market Size and Forecast
• 1.2 Market Overview
• 1.3 Market Snapshot
• 1.4 Regional Snapshot
• 1.5 Strategic Recommendations
• 1.6 Analyst Notes

2 Market Highlights

• 2.1 Key Market Highlights by Type
• 2.2 Key Market Highlights by Product
• 2.3 Key Market Highlights by Technology
• 2.4 Key Market Highlights by Application
• 2.5 Key Market Highlights by End User
• 2.6 Key Market Highlights by Process
• 2.7 Key Market Highlights by Stage
• 2.8 Key Market Highlights by Equipment
• 2.9 Key Market Highlights by Solutions

3 Market Dynamics

• 3.1 Macroeconomic Analysis
• 3.2 Market Trends
• 3.3 Market Drivers
• 3.4 Market Opportunities
• 3.5 Market Restraints
• 3.6 CAGR Growth Analysis
• 3.7 Impact Analysis
• 3.8 Emerging Markets
• 3.9 Technology Roadmap
• 3.10 Strategic Frameworks
  • 3.10.1 PORTER's 5 Forces Model
  • 3.10.2 ANSOFF Matrix
  • 3.10.3 4P's Model
  • 3.10.4 PESTEL Analysis

4 Segment Analysis

• 4.1 Market Size & Forecast by Type (2020-2035)
  • 4.1.1 Endotoxin Tests
  • 4.1.2 Sterility Tests
  • 4.1.3 Cell Line Authentication and Characterization Tests
  • 4.1.4 Adventitious Agent Detection Tests
  • 4.1.5 Residual Host Contaminant Detection Tests
  • 4.1.6 Bioburden Tests
  • 4.1.7 Others
• 4.2 Market Size & Forecast by Product (2020-2035)
  • 4.2.1 Instruments
  • 4.2.2 Kits & Reagents
  • 4.2.3 Services
  • 4.2.4 Software
  • 4.2.5 Others
• 4.3 Market Size & Forecast by Technology (2020-2035)
  • 4.3.1 PCR
  • 4.3.2 ELISA
  • 4.3.3 Western Blotting
  • 4.3.4 Chromatography
  • 4.3.5 Mass Spectrometry
  • 4.3.6 Flow Cytometry
  • 4.3.7 Others
• 4.4 Market Size & Forecast by Application (2020-2035)
  • 4.4.1 Vaccine Development
  • 4.4.2 Blood Products Testing
  • 4.4.3 Cell and Gene Therapy
  • 4.4.4 Tissue and Tissue Products
  • 4.4.5 Monoclonal Antibodies
  • 4.4.6 Recombinant Proteins
  • 4.4.7 Others
• 4.5 Market Size & Forecast by End User (2020-2035)
  • 4.5.1 Pharmaceutical Companies
  • 4.5.2 Biotechnology Companies
  • 4.5.3 Contract Research Organizations
  • 4.5.4 Academic and Research Institutes
  • 4.5.5 Others
• 4.6 Market Size & Forecast by Process (2020-2035)
  • 4.6.1 Upstream Process
  • 4.6.2 Downstream Process
  • 4.6.3 Others
• 4.7 Market Size & Forecast by Stage (2020-2035)
  • 4.7.1 Preclinical
  • 4.7.2 Clinical
  • 4.7.3 Commercial
  • 4.7.4 Others
• 4.8 Market Size & Forecast by Equipment (2020-2035)
  • 4.8.1 Automated Systems
  • 4.8.2 Manual Systems
  • 4.8.3 Others
• 4.9 Market Size & Forecast by Solutions (2020-2035)
  • 4.9.1 In-house Solutions
  • 4.9.2 Outsourced Solutions
  • 4.9.3 Others

5 Regional Analysis

• 5.1 Global Market Overview
• 5.2 North America Market Size (2020-2035)
  • 5.2.1 United States
    • 5.2.1.1 Type
    • 5.2.1.2 Product
    • 5.2.1.3 Technology
    • 5.2.1.4 Application
    • 5.2.1.5 End User
    • 5.2.1.6 Process
    • 5.2.1.7 Stage
    • 5.2.1.8 Equipment
    • 5.2.1.9 Solutions
  • 5.2.2 Canada
    • 5.2.2.1 Type
    • 5.2.2.2 Product
    • 5.2.2.3 Technology
    • 5.2.2.4 Application
    • 5.2.2.5 End User
    • 5.2.2.6 Process
    • 5.2.2.7 Stage
    • 5.2.2.8 Equipment
    • 5.2.2.9 Solutions
  • 5.2.3 Mexico
    • 5.2.3.1 Type
    • 5.2.3.2 Product
    • 5.2.3.3 Technology
    • 5.2.3.4 Application
    • 5.2.3.5 End User
    • 5.2.3.6 Process
    • 5.2.3.7 Stage
    • 5.2.3.8 Equipment
    • 5.2.3.9 Solutions
• 5.3 Latin America Market Size (2020-2035)
  • 5.3.1 Brazil
    • 5.3.1.1 Type
    • 5.3.1.2 Product
    • 5.3.1.3 Technology
    • 5.3.1.4 Application
    • 5.3.1.5 End User
    • 5.3.1.6 Process
    • 5.3.1.7 Stage
    • 5.3.1.8 Equipment
    • 5.3.1.9 Solutions
  • 5.3.2 Argentina
    • 5.3.2.1 Type
    • 5.3.2.2 Product
    • 5.3.2.3 Technology
    • 5.3.2.4 Application
    • 5.3.2.5 End User
    • 5.3.2.6 Process
    • 5.3.2.7 Stage
    • 5.3.2.8 Equipment
    • 5.3.2.9 Solutions
  • 5.3.3 Rest of Latin America
    • 5.3.3.1 Type
    • 5.3.3.2 Product
    • 5.3.3.3 Technology
    • 5.3.3.4 Application
    • 5.3.3.5 End User
    • 5.3.3.6 Process
    • 5.3.3.7 Stage
    • 5.3.3.8 Equipment
    • 5.3.3.9 Solutions
• 5.4 Asia-Pacific Market Size (2020-2035)
  • 5.4.1 China
    • 5.4.1.1 Type
    • 5.4.1.2 Product
    • 5.4.1.3 Technology
    • 5.4.1.4 Application
    • 5.4.1.5 End User
    • 5.4.1.6 Process
    • 5.4.1.7 Stage
    • 5.4.1.8 Equipment
    • 5.4.1.9 Solutions
  • 5.4.2 India
    • 5.4.2.1 Type
    • 5.4.2.2 Product
    • 5.4.2.3 Technology
    • 5.4.2.4 Application
    • 5.4.2.5 End User
    • 5.4.2.6 Process
    • 5.4.2.7 Stage
    • 5.4.2.8 Equipment
    • 5.4.2.9 Solutions
  • 5.4.3 South Korea
    • 5.4.3.1 Type
    • 5.4.3.2 Product
    • 5.4.3.3 Technology
    • 5.4.3.4 Application
    • 5.4.3.5 End User
    • 5.4.3.6 Process
    • 5.4.3.7 Stage
    • 5.4.3.8 Equipment
    • 5.4.3.9 Solutions
  • 5.4.4 Japan
    • 5.4.4.1 Type
    • 5.4.4.2 Product
    • 5.4.4.3 Technology
    • 5.4.4.4 Application
    • 5.4.4.5 End User
    • 5.4.4.6 Process
    • 5.4.4.7 Stage
    • 5.4.4.8 Equipment
    • 5.4.4.9 Solutions
  • 5.4.5 Australia
    • 5.4.5.1 Type
    • 5.4.5.2 Product
    • 5.4.5.3 Technology
    • 5.4.5.4 Application
    • 5.4.5.5 End User
    • 5.4.5.6 Process
    • 5.4.5.7 Stage
    • 5.4.5.8 Equipment
    • 5.4.5.9 Solutions
  • 5.4.6 Taiwan
    • 5.4.6.1 Type
    • 5.4.6.2 Product
    • 5.4.6.3 Technology
    • 5.4.6.4 Application
    • 5.4.6.5 End User
    • 5.4.6.6 Process
    • 5.4.6.7 Stage
    • 5.4.6.8 Equipment
    • 5.4.6.9 Solutions
  • 5.4.7 Rest of APAC
    • 5.4.7.1 Type
    • 5.4.7.2 Product
    • 5.4.7.3 Technology
    • 5.4.7.4 Application
    • 5.4.7.5 End User
    • 5.4.7.6 Process
    • 5.4.7.7 Stage
    • 5.4.7.8 Equipment
    • 5.4.7.9 Solutions
• 5.5 Europe Market Size (2020-2035)
  • 5.5.1 Germany
    • 5.5.1.1 Type
    • 5.5.1.2 Product
    • 5.5.1.3 Technology
    • 5.5.1.4 Application
    • 5.5.1.5 End User
    • 5.5.1.6 Process
    • 5.5.1.7 Stage
    • 5.5.1.8 Equipment
    • 5.5.1.9 Solutions
  • 5.5.2 France
    • 5.5.2.1 Type
    • 5.5.2.2 Product
    • 5.5.2.3 Technology
    • 5.5.2.4 Application
    • 5.5.2.5 End User
    • 5.5.2.6 Process
    • 5.5.2.7 Stage
    • 5.5.2.8 Equipment
    • 5.5.2.9 Solutions
  • 5.5.3 United Kingdom
    • 5.5.3.1 Type
    • 5.5.3.2 Product
    • 5.5.3.3 Technology
    • 5.5.3.4 Application
    • 5.5.3.5 End User
    • 5.5.3.6 Process
    • 5.5.3.7 Stage
    • 5.5.3.8 Equipment
    • 5.5.3.9 Solutions
  • 5.5.4 Spain
    • 5.5.4.1 Type
    • 5.5.4.2 Product
    • 5.5.4.3 Technology
    • 5.5.4.4 Application
    • 5.5.4.5 End User
    • 5.5.4.6 Process
    • 5.5.4.7 Stage
    • 5.5.4.8 Equipment
    • 5.5.4.9 Solutions
  • 5.5.5 Italy
    • 5.5.5.1 Type
    • 5.5.5.2 Product
    • 5.5.5.3 Technology
    • 5.5.5.4 Application
    • 5.5.5.5 End User
    • 5.5.5.6 Process
    • 5.5.5.7 Stage
    • 5.5.5.8 Equipment
    • 5.5.5.9 Solutions
  • 5.5.6 Rest of Europe
    • 5.5.6.1 Type
    • 5.5.6.2 Product
    • 5.5.6.3 Technology
    • 5.5.6.4 Application
    • 5.5.6.5 End User
    • 5.5.6.6 Process
    • 5.5.6.7 Stage
    • 5.5.6.8 Equipment
    • 5.5.6.9 Solutions
• 5.6 Middle East & Africa Market Size (2020-2035)
  • 5.6.1 Saudi Arabia
    • 5.6.1.1 Type
    • 5.6.1.2 Product
    • 5.6.1.3 Technology
    • 5.6.1.4 Application
    • 5.6.1.5 End User
    • 5.6.1.6 Process
    • 5.6.1.7 Stage
    • 5.6.1.8 Equipment
    • 5.6.1.9 Solutions
  • 5.6.2 United Arab Emirates
    • 5.6.2.1 Type
    • 5.6.2.2 Product
    • 5.6.2.3 Technology
    • 5.6.2.4 Application
    • 5.6.2.5 End User
    • 5.6.2.6 Process
    • 5.6.2.7 Stage
    • 5.6.2.8 Equipment
    • 5.6.2.9 Solutions
  • 5.6.3 South Africa
    • 5.6.3.1 Type
    • 5.6.3.2 Product
    • 5.6.3.3 Technology
    • 5.6.3.4 Application
    • 5.6.3.5 End User
    • 5.6.3.6 Process
    • 5.6.3.7 Stage
    • 5.6.3.8 Equipment
    • 5.6.3.9 Solutions
  • 5.6.4 Sub-Saharan Africa
    • 5.6.4.1 Type
    • 5.6.4.2 Product
    • 5.6.4.3 Technology
    • 5.6.4.4 Application
    • 5.6.4.5 End User
    • 5.6.4.6 Process
    • 5.6.4.7 Stage
    • 5.6.4.8 Equipment
    • 5.6.4.9 Solutions
  • 5.6.5 Rest of MEA
    • 5.6.5.1 Type
    • 5.6.5.2 Product
    • 5.6.5.3 Technology
    • 5.6.5.4 Application
    • 5.6.5.5 End User
    • 5.6.5.6 Process
    • 5.6.5.7 Stage
    • 5.6.5.8 Equipment
    • 5.6.5.9 Solutions

6 Market Strategy

• 6.1 Demand-Supply Gap Analysis
• 6.2 Trade & Logistics Constraints
• 6.3 Price-Cost-Margin Trends
• 6.4 Market Penetration
• 6.5 Consumer Analysis
• 6.6 Regulatory Snapshot

7 Competitive Intelligence

• 7.1 Market Positioning
• 7.2 Market Share
• 7.3 Competition Benchmarking
• 7.4 Top Company Strategies

8 Company Profiles

• 8.1 Charles River Laboratories
  • 8.1.1 Overview
  • 8.1.2 Product Summary
  • 8.1.3 Financial Performance
  • 8.1.4 SWOT Analysis
• 8.2 Thermo Fisher Scientific
  • 8.2.1 Overview
  • 8.2.2 Product Summary
  • 8.2.3 Financial Performance
  • 8.2.4 SWOT Analysis
• 8.3 Merck KGaA
  • 8.3.1 Overview
  • 8.3.2 Product Summary
  • 8.3.3 Financial Performance
  • 8.3.4 SWOT Analysis
• 8.4 Sartorius AG
  • 8.4.1 Overview
  • 8.4.2 Product Summary
  • 8.4.3 Financial Performance
  • 8.4.4 SWOT Analysis
• 8.5 Lonza Group
  • 8.5.1 Overview
  • 8.5.2 Product Summary
  • 8.5.3 Financial Performance
  • 8.5.4 SWOT Analysis
• 8.6 Bio-Rad Laboratories
  • 8.6.1 Overview
  • 8.6.2 Product Summary
  • 8.6.3 Financial Performance
  • 8.6.4 SWOT Analysis
• 8.7 WuXi AppTec
  • 8.7.1 Overview
  • 8.7.2 Product Summary
  • 8.7.3 Financial Performance
  • 8.7.4 SWOT Analysis
• 8.8 Eurofins Scientific
  • 8.8.1 Overview
  • 8.8.2 Product Summary
  • 8.8.3 Financial Performance
  • 8.8.4 SWOT Analysis
• 8.9 SGS SA
  • 8.9.1 Overview
  • 8.9.2 Product Summary
  • 8.9.3 Financial Performance
  • 8.9.4 SWOT Analysis
• 8.10 Pace Analytical Services
  • 8.10.1 Overview
  • 8.10.2 Product Summary
  • 8.10.3 Financial Performance
  • 8.10.4 SWOT Analysis
• 8.11 Cygnus Technologies
  • 8.11.1 Overview
  • 8.11.2 Product Summary
  • 8.11.3 Financial Performance
  • 8.11.4 SWOT Analysis
• 8.12 Toxikon Corporation
  • 8.12.1 Overview
  • 8.12.2 Product Summary
  • 8.12.3 Financial Performance
  • 8.12.4 SWOT Analysis
• 8.13 Sartorius Stedim Biotech
  • 8.13.1 Overview
  • 8.13.2 Product Summary
  • 8.13.3 Financial Performance
  • 8.13.4 SWOT Analysis
• 8.14 GE Healthcare
  • 8.14.1 Overview
  • 8.14.2 Product Summary
  • 8.14.3 Financial Performance
  • 8.14.4 SWOT Analysis
• 8.15 Danaher Corporation
  • 8.15.1 Overview
  • 8.15.2 Product Summary
  • 8.15.3 Financial Performance
  • 8.15.4 SWOT Analysis
• 8.16 GenScript Biotech
  • 8.16.1 Overview
  • 8.16.2 Product Summary
  • 8.16.3 Financial Performance
  • 8.16.4 SWOT Analysis
• 8.17 Creative Bioarray
  • 8.17.1 Overview
  • 8.17.2 Product Summary
  • 8.17.3 Financial Performance
  • 8.17.4 SWOT Analysis
• 8.18 Nelson Laboratories
  • 8.18.1 Overview
  • 8.18.2 Product Summary
  • 8.18.3 Financial Performance
  • 8.18.4 SWOT Analysis
• 8.19 Microbac Laboratories
  • 8.19.1 Overview
  • 8.19.2 Product Summary
  • 8.19.3 Financial Performance
  • 8.19.4 SWOT Analysis
• 8.20 Paragon Bioservices
  • 8.20.1 Overview
  • 8.20.2 Product Summary
  • 8.20.3 Financial Performance
  • 8.20.4 SWOT Analysis

9 About Us

• 9.1 About Us
• 9.2 Research Methodology
• 9.3 Research Workflow
• 9.4 Consulting Services
• 9.5 Our Clients
• 9.6 Client Testimonials
• 9.7 Contact Us